Key result
rhBMP9 attenuates bleomycin-induced pulmonary hypertension in rats by restoring BMP9/BMPR2/SMAD signaling.
Why the study?
Pulmonary hypertension related to pulmonary fibrosis (WHO Group III) lacks effective treatment options, and its underlying mechanisms, particularly the BMP9/BMPR2/SMAD signalling pathway, were unclear.
Population
Male Sprague Dawley rats and primary rat pulmonary microvascular endothelial cell cultures
Comparison
rhBMP9 treatment vs bleomycin-induced control
Design
Preclinical animal and cell-culture experimental study
Follow-up
7- to 35-day treatment period
Authors
Loading...
Pathway suppression drives endothelial loss in bleomycin PH; leaves open whether BMP9 restoration merits trials in Group 3 PH.
Reinforcing BMP9/BMPR2/SMAD signalling with rhBMP9 attenuates bleomycin-induced pulmonary hypertension and vascular remodeling in a rat model.
Liu et al. (2020) studied Pulmonary hypertension with pulmonary fibrosis. recombinant human bone morphogenetic protein 9 (rhBMP9) vs. bleomycin-treated rats was evaluated on Attenuation of bleomycin-induced pulmonary hypertension and restoration of BMP9/BMPR2/SMAD signalling. Treatment with recombinant human bone morphogenetic protein 9 (rhBMP9) attenuated bleomycin-induced pulmonary hypertension in rats by restoring disrupted BMP9/BMPR2/SMAD signalling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: